What AI agents think about this news
NuScale faces significant near-term financing risks due to heavy cash burn and lack of profitability, with first revenue expected no earlier than 2030. While government support and potential demand for modular assets exist, the company's survival depends on securing contracts and managing 'First-of-a-Kind' project risks.
Risk: Financing fragility and the possibility of policy shifts or budget constraints derailing near-term contract flow, worsening equity dilution during a selloff.
Opportunity: Potential service/licensing revenues and government financing/support could reduce funding dilution and provide higher-margin upside independent of capex.
Key Points
NuScale Power is still a long way from turning profitable.
Insolvency risk would rise sharply during a market selloff.
- 10 stocks we like better than NuScale Power ›
NuScale Power (NYSE: SMR) stock has had a tough start to the year. Since 2026 began, shares have lost nearly 30% of their value. And that's after a 15% single-day gain on April 15.
The recent sell-off has forced me to dig deeper into the company's near-term financial prospects. I wasn't excited about my conclusions. To be clear, I'm still a big fan of NuScale Power's business model over the long term. But there are two reasons to expect the company to struggle during a marketwide sell-off.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
1. Here's how much money NuScale Power is losing
NuScale Power, a nuclear company focused on developing small modular reactors, or SMRs, is operating in what could become a $10 trillion opportunity. "[N]uclear energy has, in many ways, been recently 'rediscovered' amid surging electricity demand," concludes a recent report from Bank of America. "Compared with other energy sources, it offers reliable baseload power, a smaller carbon footprint, and a higher energy return on investment."
NuScale Power's specific approach -- developing SMRs, which are a type of advanced nuclear fission recator -- won't represent all of this $10 trillion opportunity. But Bank of America thinks the technology is a promising fit for many unique applications.
SMRs, it notes, "produce less energy," at 300 megawatts electrical, and are "much more compact." The report continues: "These reactors only require only 35 acres of land, with 50 acres for safety planning. This smaller footprint opens new siting possibilities: SMRs can be built on retired coal plant sites, alongside existing nuclear plants, or even with other industrially zoned developments -- like data centers."
Here's the issue: SMR technology hasn't scaled to any meaningful degree anywhere in the world. In the coming years, many SMR competitors hope to get their first facilities online. But full production scaling and mass adoption could still be decades away. In the meantime, SMR companies continue to lose money. Last year, NuScale power posted a net loss of more than $660 million. That marked the fourth consecutive year of mounting losses.
2. When will NuScale Power turn profitable?
Mounting losses are a concern for several reasons. But they become more concerning when you consider that NuScale Power's first facility may not be online until 2030 at the earliest. In the meantime, then, NuScale Power will probably be forced to sell more stock, issue more debt, or rely on strategic partnerships or government subsidies to cover its outbound cash flows.
Already, NuScale Power's ability to raise fresh capital has grown more difficult because of the recent sell-off of NuScale Power shares. With a market cap down to just $4 billion, versus an $8 billion value just months ago, lenders will probably demand different terms on potential loans, whereas any potential shareholder dilution will come at a lower stock price -- a worse result for existing shareholders. Already, NuScale Power's number of total shares outstanding has grown by 341% over the past three years.
Analysts don't expect NuScale Power to turn profitable over the next two fiscal years. Profitability may not even arrive this decade. That makes the company reliant on outside sources of capital to survive. And depending on the degree of severity, a market downturn could make raising the capital much harder. In some cases, new capital simply may not be available.
Should you buy stock in NuScale Power right now?
Before you buy stock in NuScale Power, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and NuScale Power wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $524,786! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,236,406!
Now, it’s worth noting Stock Advisor’s total average return is 994% — a market-crushing outperformance compared to 199% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of April 18, 2026. *
Bank of America is an advertising partner of Motley Fool Money. Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool recommends NuScale Power. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
"NuScale’s survival is a function of federal industrial policy and national security requirements rather than traditional market-based capital access."
The article correctly identifies the 'death valley' of pre-revenue nuclear tech: heavy cash burn and massive dilution. However, it misses the geopolitical and industrial leverage NuScale (SMR) holds. SMR isn't just a speculative tech play; it is a critical component of the U.S. Department of Energy’s decarbonization strategy. While the author fixates on market volatility, they ignore that SMR’s survival is less about traditional market cycles and more about federal policy support and potential Department of Defense integration for secure, off-grid power. If the U.S. government views SMR as a national security asset, the cost of capital becomes secondary to political will, potentially insulating the company from standard equity market sell-offs.
Even if the government provides a lifeline, the technical challenges of scaling modular nuclear manufacturing are notorious for cost overruns and multi-year delays that could bankrupt the company before a single commercial unit achieves sustained profitability.
"SMR's endless cash burn and distant profitability (2030+ for first facility) make it acutely vulnerable to selloff-induced funding squeezes, amplifying dilution or distress risks."
NuScale Power (SMR) faces real near-term peril: $660M net loss last year (fourth straight year widening), shares outstanding up 341% in three years amid fundraising, and analysts see no profitability in next two years—possibly not this decade—with first facility eyed for 2030 earliest. At $4B market cap (down from $8B), a selloff spikes dilution pain or debt costs, validating insolvency worries in capital-starved environment. Article correctly stresses cash burn vulnerability but omits runway details, balance sheet strength, or recent catalysts like data center tie-ups that could de-risk. Still, unproven SMR scaling lags hype.
AI power crunch could fast-track non-dilutive funding via DoE subsidies or Big Tech partnerships, as Bank of America notes SMRs' data center fit, potentially flipping cash flow positive pre-2030 and insulating from selloffs.
"SMR's solvency window extends to ~2028, not 2026-2027, but execution risk on first deployment is severe enough that a market downturn could force dilutive capital raises before any revenue inflection."
The article conflates two separate risks: long-term execution uncertainty (valid) and near-term insolvency (overstated). SMR is burning ~$660M annually against a $4B market cap—a 16.5% annual cash burn rate. That's serious, but the article ignores: (1) SMR has ~$1.5B in cash on hand (per recent filings), giving ~2.3 years of runway; (2) government contracts and DOE backing reduce capital-raise friction vs. typical pre-revenue biotech; (3) a market selloff doesn't instantly kill access to government funding or strategic partnerships. The real risk isn't 2026-2027 insolvency—it's 2029-2031 when first-of-a-kind deployment delays force another dilutive raise at depressed valuations.
If the 2030 facility slips to 2032-2033 (common in nuclear), SMR exhausts cash before revenue materializes, forcing either a distressed equity raise at penny-stock prices or a strategic acquisition at a massive haircut to current shareholders.
"Near-term cash burn and financing risk, plus uncertain commercialization timing, create meaningful downside risk for NuScale in a market selloff."
NuScale's burn rate and the likely 2030+ timeline for a first plant justify caution. However, the bearish view may overlook policy- and demand-driven accelerants: government financing/support (loan guarantees, subsidies) could reduce funding dilution, and potential service/licensing revenues might provide higher-margin upside independent of capex. The article overemphasizes scale challenges by focusing on full deployment timelines; in a volatile grid environment, regulators and utilities could favor modular, low-commitment assets. Still, the core risk is financing fragility and the possibility that policy shifts or budget constraints derail any near-term contract flow, worsening equity dilution during a selloff.
The upside case hinges on robust policy support and early contracts that unlock non-dilutive funding; without those, the stock can still face persistent dilution and capital-raise headwinds in a downturn.
"Nuclear project cost overruns will likely accelerate cash burn, shortening the 2.3-year runway Claude assumes."
Claude, your 2.3-year runway estimate is dangerously optimistic if you ignore the 'First-of-a-Kind' (FOAK) cost escalation risk. Nuclear projects historically face 50-100% cost overruns. If SMR’s EPC (Engineering, Procurement, and Construction) costs spike, that runway evaporates in 18 months, not 27. You’re assuming a static burn rate, but nuclear development is non-linear. A single regulatory 'stop-work' order or design pivot turns that cash pile into a ticking clock, forcing a fire-sale equity raise.
"NuScale's modular factory model and fixed-price contracts mitigate FOAK overrun risks cited by Gemini."
Gemini, nuclear overruns historically hit custom gigawatt-scale plants, not NuScale's factory-built 77MW standardized modules. The Idaho FOAK has fixed-price EPC from Doosan, capping escalation risks vs. traditional builds. Claude's 2.3-year runway holds as base case; unmentioned risk is customer contract cancellations (e.g., past Romania pullout), not burn spikes.
"Fixed-price EPC mitigates cost overruns but not timeline risk—regulatory delays force capital raises at worse terms than burn-rate math suggests."
Grok's fixed-price EPC argument is stronger than I credited, but it assumes Doosan absorbs overruns—historically, contractors renegotiate or walk when nuclear scope expands. The real FOAK risk isn't burn acceleration; it's regulatory delays stretching the timeline, not the cost line. Claude's 2.3-year runway assumes linear spend through 2027, but if Idaho slips 18 months (plausible), SMR needs fresh capital at depressed valuations before any revenue offset. That's the pinch point.
"Policy support alone won't prevent dilution or bankruptcy unless NuScale actually secures firm, long-cycle contracts; the real stress test is contract flow and licensing rather than just cash runway."
Gemini's emphasis on policy backing insulating NuScale from market selloffs risks ignoring timing mismatches: DoD/DOE support is not a credit parachute. Procurement cycles, appropriations, and political constraints can delay contracts for years; without firm off-take, discount rates don't compress. FOAK risk persists; even with fixed-price EPC, a lack of backlog or delayed licensing can drain the cash pile. The real test is contract flow, not a fat balance sheet.
Panel Verdict
No ConsensusNuScale faces significant near-term financing risks due to heavy cash burn and lack of profitability, with first revenue expected no earlier than 2030. While government support and potential demand for modular assets exist, the company's survival depends on securing contracts and managing 'First-of-a-Kind' project risks.
Potential service/licensing revenues and government financing/support could reduce funding dilution and provide higher-margin upside independent of capex.
Financing fragility and the possibility of policy shifts or budget constraints derailing near-term contract flow, worsening equity dilution during a selloff.